Načítá se...
Emerging agents for the treatment of metastatic urothelial cancer
Over the past few decades, platinum-based combination chemotherapy (PBCC) has been the preferred initial therapy for metastatic urothelial cancer (mUC). However, despite a response rate of approximately 50%, a small proportion of patients with distant metastases may be cured by cisplatin-based combi...
Uloženo v:
| Vydáno v: | Investig Clin Urol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Korean Urological Association
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100010/ https://ncbi.nlm.nih.gov/pubmed/33943047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.20200597 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|